Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IDRSF,357847000,166904992,,,-138607000,,-138833000,40539000,-87345000,-128046000,-128046000,,-2705000,,,,226000,6965000,135011000,94310000,-10561000,,-138833000,-138833000,3233000,1981443000,825468000,361080000,19769000,1186548000,8365000,31454000,-1590848000,76513000,-37880000,14740000,163532000,118928000,-37880000,200173000,965699000,2703000,765120000,5593000,591546000,11340000,169535000.0,-25000.0,154962000.0,6742000.0,11181000.0,6751000.0,35867000.0,-203000.0,-125634000.0,4130000.0,-1659000.0,-9000.0,-2542000.0,-12276000.0,,846771000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,23.5,1630525478,0.049999237,24.0,24.0,23.5,23097,23.45,0.0,0.0,0,0,finmb_418070523,Other OTC,Idorsia Ltd,CHF,1158,3505,0.8199997,0.03615519,22.68 - 33.25,-9.75,-0.2932331,22.68,33.25,PRE,us_market,IDORSIA LTD,0,False,False,2,0.21321636,23.5 - 24.0,-3.084,2.929,25.15,-1.6499996,-0.06560635,26.807684,-3.307684,-0.12338567,3922267392,8.023216,15,America/New_York,EDT,-14400000,0.72,,,33.25,22.68,25.15,26.81,1.16k,3.5k,166.9M,,96.65M,36.53%,25.50%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,753.18%",-25.63%,-146.42%,27.43M,0.17,-86.90%,-309.32M,-464.33M,-498.81M,-3.08,,928.65M,5.55,638.5M,176.83,8.12,2.93,-490.76M,-304.28M,Value,4123,Healthcare,8,6,"Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.",Allschwil,41 58 844 00 00,1,1625097600,3,Switzerland,http://www.idorsia.com,86400,4,Hegenheimermattweg 91,Biotechnology
t-1,IDRSF,488398000,166904992,,,-103925000,,-104531000,30974000,-90586000,-121798000,-121798000,,-2299000,,,,606000,6866000,128664000,97452000,17873000,,-104531000,-104531000,491000,1970328000,809019000,488889000,20731000,1297908000,8345000,23667000,-1452016000,76937000,-37768000,205343000,127665000,101858000,-37768000,192036000,897099000,2939000,741062000,4705000,589433000,10420000,137118000.0,-852000.0,134566000.0,2099000.0,-56616000.0,2104000.0,-13145000.0,337000.0,-150147000.0,4297000.0,330000.0,-5000.0,5145000.0,-2524000.0,-1000.0,795241000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,23.5,1630525478,0.049999237,24.0,24.0,23.5,23097,23.45,0.0,0.0,0,0,finmb_418070523,Other OTC,Idorsia Ltd,CHF,1158,3505,0.8199997,0.03615519,22.68 - 33.25,-9.75,-0.2932331,22.68,33.25,PRE,us_market,IDORSIA LTD,0,False,False,2,0.21321636,23.5 - 24.0,-3.084,2.929,25.15,-1.6499996,-0.06560635,26.807684,-3.307684,-0.12338567,3922267392,8.023216,15,America/New_York,EDT,-14400000,0.72,,,33.25,22.68,25.15,26.81,1.16k,3.5k,166.9M,,96.65M,36.53%,25.50%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,753.18%",-25.63%,-146.42%,27.43M,0.17,-86.90%,-309.32M,-464.33M,-498.81M,-3.08,,928.65M,5.55,638.5M,176.83,8.12,2.93,-490.76M,-304.28M,Value,4123,Healthcare,8,6,"Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.",Allschwil,41 58 844 00 00,1,1625097600,3,Switzerland,http://www.idorsia.com,86400,4,Hegenheimermattweg 91,Biotechnology
t-2,IDRSF,584900000,166904992,,,-141522000,,-136962000,33710000,-85662000,-119655000,-119655000,,-2643000,,,,-4560000,5823000,125478000,91485000,-21867000,,-136962000,-136962000,583000,1962739000,849882000,585483000,19158000,1435365000,8324000,7138000,-1347484000,91950000,-38096000,201077000,140810000,127467000,-38096000,196224000,1034627000,2854000,869215000,4568000,587352000,11117000,-207282000.0,-1592000.0,-404494000.0,520702000.0,8194000.0,520703000.0,-7400000.0,-229000.0,-123380000.0,3420000.0,381000.0,-1000.0,-135000.0,-3710000.0,-193552000.0,907160000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,23.5,1630525478,0.049999237,24.0,24.0,23.5,23097,23.45,0.0,0.0,0,0,finmb_418070523,Other OTC,Idorsia Ltd,CHF,1158,3505,0.8199997,0.03615519,22.68 - 33.25,-9.75,-0.2932331,22.68,33.25,PRE,us_market,IDORSIA LTD,0,False,False,2,0.21321636,23.5 - 24.0,-3.084,2.929,25.15,-1.6499996,-0.06560635,26.807684,-3.307684,-0.12338567,3922267392,8.023216,15,America/New_York,EDT,-14400000,0.72,,,33.25,22.68,25.15,26.81,1.16k,3.5k,166.9M,,96.65M,36.53%,25.50%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,753.18%",-25.63%,-146.42%,27.43M,0.17,-86.90%,-309.32M,-464.33M,-498.81M,-3.08,,928.65M,5.55,638.5M,176.83,8.12,2.93,-490.76M,-304.28M,Value,4123,Healthcare,8,6,"Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.",Allschwil,41 58 844 00 00,1,1625097600,3,Switzerland,http://www.idorsia.com,86400,4,Hegenheimermattweg 91,Biotechnology
t-3,IDRSF,209222000,166904992,,,-119434000,,-118481000,25916000,-85141000,-111345000,-111345000,,-2343000,,,,-953000,7773000,119118000,92914000,-8089000,,-118481000,-118481000,776000,1437422000,838887000,209998000,44272000,1048885000,7133000,15738000,-1210523000,83129000,-24034000,9269000,148210000,128722000,-24034000,194251000,838234000,6355000,667646000,6640000,585237000,11987000,-144032000.0,3608000.0,-145862000.0,4916000.0,8449000.0,4916000.0,-232696000.0,-153000.0,-91597000.0,4664000.0,6303000.0,-1000.0,1756000.0,-1764000.0,-1000.0,709512000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,23.5,1630525478,0.049999237,24.0,24.0,23.5,23097,23.45,0.0,0.0,0,0,finmb_418070523,Other OTC,Idorsia Ltd,CHF,1158,3505,0.8199997,0.03615519,22.68 - 33.25,-9.75,-0.2932331,22.68,33.25,PRE,us_market,IDORSIA LTD,0,False,False,2,0.21321636,23.5 - 24.0,-3.084,2.929,25.15,-1.6499996,-0.06560635,26.807684,-3.307684,-0.12338567,3922267392,8.023216,15,America/New_York,EDT,-14400000,0.72,,,33.25,22.68,25.15,26.81,1.16k,3.5k,166.9M,,96.65M,36.53%,25.50%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,753.18%",-25.63%,-146.42%,27.43M,0.17,-86.90%,-309.32M,-464.33M,-498.81M,-3.08,,928.65M,5.55,638.5M,176.83,8.12,2.93,-490.76M,-304.28M,Value,4123,Healthcare,8,6,"Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.",Allschwil,41 58 844 00 00,1,1625097600,3,Switzerland,http://www.idorsia.com,86400,4,Hegenheimermattweg 91,Biotechnology
